EIKN
Eikon TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Composite grade A from latest DB weights. Momentum 80.9 / Value 46.4
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +8.8.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
81
Value
46
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $24.80
Why
Momentum81 · Δ7d +8.8
Value46 · Δ7d +0.0
SentimentN/A · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
81
40% active weight
Current posture
7d trendSoftening
Δ7d
+8.8
Δ21d
+71.6
Value
46
60% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.0
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 80.9 / Value 46.4
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$536.51M
Beta
-
Shares Out
54.14M
P/E (TTM) · Derived
-1.6
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
-
EPS YoY
+3.7%
Gross Margin
-
Op Margin
-
Net Debt
-$79.06M
Current Ratio
11.75
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology